PS02.214: ANALYSIS OF PROGNOSTIC FACTORS IN RECURRENCE CASES AFTER SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA. (14th September 2018)

• Record Type: Journal Article
• Authors: Nishiyama, Mitsuo; Takeda, Shigeru; Kanekiyo, Shinsuke; Kitahara, Masahiro; Iida, Michihisa; Tokumitsu, Yukio; Tomochika, Shinobu; Tokuhisa, Yoshihiro; Suzuki, Nobuaki; Yoshino, Shigefumi; Hazama, Shoichi; Ueno, Tomio; Nagano, Hiroaki
• Is Part Of: Diseases of the esophagus. Volume 31(2018)Supplement 1
• Page Start: 182
• Page End: 183
• Publication Date: 2018-09-14
• Subjects: Esophageal squamous cell carcinoma -- recurrence; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1093/dote/doy089.PS02.214
• Languages: English
• ISSNs: 1120-8694

Abstract

Abstract: Background: Esophageal cancer is one of the most malignant gastrointestinal cancers and prognosis in recurrent cases remains extremely poor. However some studies show a relatively favorable prognosis among patients with solitary recurrence site who undergo locoregional therapy. It is important to clarify prognostic factors in postrecurrence cases. Methods: This study included 156 patients who underwent curative resection for esophageal squamous cell carcinoma from January 2005 to December 2014. In this retrospective study we analysed relationship between clinicopathologic factors and prognosis after recurrence among these 156 patients. Results: The average age was 65.2 years (± 8.2), 34 males, 11 females, The frequency of recurrence is pStage I: 2/36 cases (5.6%), pStage II: 7/48 cases (15%), pStage III: 21/43 cases (49%), pStage IVa: 8/11 cases (73%). Median survival time after recurrence was 377 (29 - 3266 days), and a 1 year/2 years/3 year survival rate after relapse was 50%/24%/11%. Patients with recurrent disease were offered treatment with chemotherapy + surgery (5 cases, 11%), chemotherapy + radiation (17 cases, 38%), chemotherapy (18 cases, 40%) and BSC (5 cases, 11%). MST was not reached in the chemotherapy + surgery group (741- 3266 days), 431 days (91–2324 days) in the chemotherapy + radiation group, 223 days (85–1079 days) in the chemotherapy group, and 52 days in the BSC group. There was a significant difference between each groups ( P < 0.03). In univariate analysis, age (≤ 65/ > 65) single/multiple site recurrence, presence or absence of postoperative pneumonia, presence or absence of ARDS was selected as a prognostic factor after recurrence. In multivariate analysis, single/multiple site recurrence(HR 10.2, 95%CI 2.619–39.8, P = 0.0008), Postoperative pneumonia (HR 3.6, 95% CI 1.186 - 10.867, P = 0.024), postoperative ARDS (HR 5.6, 95% CI 1.209 - 26, 3, P = 0.0276) was selected. Conclusion: Postoperative pulmonary complications might be related and aggressive local control for single site recurrence might improve the prognosis after recurrence of thoracic esophageal squamous cell carcinoma. Disclosure: All authors have declared no conflicts of interest.